Trace leptin from adipose tissue to appetite circuits, distinguish hormone deficiency from impaired response, and apply testing and treatment limits.
How can someone have abundant leptin and still feel hungry? Start by separating the hormone in blood from the response it produces. Leptin reports energy sufficiency, but it is one input to appetite and endocrine regulation. A low concentration, an ineffective receptor and reduced responsiveness are different problems.
Read the adipocyte's energy report
Leptin reports available energy, not the size of the last meal. White adipocytes release this protein hormone, encoded by LEP. Across people, more body fat generally accompanies more circulating leptin. Considine and colleagues documented that association in humans. It explains why most people with common obesity have plentiful leptin rather than a missing hormone. It does not tell us how strongly an individual brain responds. [1]
Fat mass provides the background report. Recent energy intake changes it too. During fasting, leptin can fall substantially before a large amount of body fat disappears. Nutritional and insulin-related signals help adipocytes adjust secretion. Think of stored fuel and current fuel delivery as separate inputs. Someone can still have substantial reserves while the signal reports reduced availability. A low result after sustained restriction therefore does not, by itself, identify an inherited hormone defect. [2]
Circulating leptin must reach responsive central circuits, including hypothalamic pathways. Blood concentration is only one part of this journey. Access to the brain, receptor function and intracellular responses all matter. Human cerebrospinal-fluid observations support a possible transport limitation in obesity, but a blood sample cannot locate that limitation in one patient. Leptin also participates in a wider network involving brainstem pathways, insulin, ghrelin, gut signals and reward processing. Experiments in animals demonstrate leptin effects in hindbrain and reward-related circuits, reinforcing the limits of a two-neuron drawing. [18][23][24]
Read two things together. How much adipose tissue is present, and has energy availability recently changed?
Worked example. During a supervised three-day fasting experiment, a participant's leptin declines much more than measured fat mass. Reduced nutrient availability can change adipocyte secretion before substantial tissue loss. The result fits an acute energy signal rather than disappearance of adipocytes. This is a research observation, not a recommendation to undertake prolonged fasting. [2]
Predict whether refeeding must wait for substantial fat gain to affect leptin
No. Nutritional regulation can change leptin before large changes in fat mass. The signal is sensitive to current energy availability as well as stored energy.
Follow activation and inhibition separately
The long form of the leptin receptor, LEPRb or Ob-Rb, is a cytokine-family receptor. It uses an associated kinase, JAK2, rather than an intrinsic receptor tyrosine kinase. Leptin binding initiates phosphorylation events that recruit and activate STAT3. Activated STAT3 forms dimers and enters the nucleus and changes transcription. This is a major energy-balance pathway, but other intracellular pathways and changes in neuronal firing also contribute. [3][17]
In the simplified arcuate circuit, effective leptin signaling supports POMC/CART neurons. POMC is proopiomelanocortin, a precursor from which alpha-melanocyte-stimulating hormone, alpha-MSH, is produced. Alpha-MSH activates downstream MC4R, the melanocortin-4 receptor, supporting lower food intake. CART names a coexpressed peptide; it is not the precursor of alpha-MSH. Mouse electrophysiology helps establish these relationships, but this drawing is not the entire human appetite network. [4]
The opposing population expresses NPY and AgRP. NPY, neuropeptide Y, promotes food intake. AgRP, agouti-related peptide, opposes melanocortin signaling at MC4R. Leptin inhibits this orexigenic population. Therefore, less AgRP means less opposition to alpha-MSH. Do not draw AgRP as an MC4R activator or make NPY the same molecule as AgRP. [4][5]
Here, an arrow means activation or promotion; a flat-ended line means inhibition. During energy deficit, reduced leptin input weakens POMC support and releases NPY/AgRP from inhibition. These are relative tendencies, not an on/off switch that predicts a person's next meal. A defect after LEPR can also interrupt the pathway despite adequate hormone. [4][17]
Worked example. A receptor-bearing research cell binds leptin but cannot activate JAK2. Hormone arrival is intact; intracellular signaling is interrupted. Adding ligand cannot repair that experimentally disabled step. In a separate intact circuit, increasing AgRP would oppose alpha-MSH at MC4R even when POMC produces its peptide.
Predict the direction of MC4R signaling when AgRP falls and alpha-MSH stays constant
Less AgRP means less antagonism at MC4R. The same alpha-MSH input can therefore produce more melanocortin signaling in this simplified model.
Locate the missing function
Congenital LEP deficiency is a ligand problem. Severe hunger and rapid weight gain beginning in infancy, especially with very low leptin despite abundant fat, warrant specialist genetic evaluation. Montague's 1997 report described two related children with a homozygous frameshift in LEP. That small family study established a human mechanism, not the frequency of the disorder in everyone with obesity. Some individuals with severe congenital deficiency have impaired T-cell responses or pubertal delay; findings depend on age and phenotype. [6][8]
LEPR deficiency is a receptor problem. Adipocytes may still produce leptin appropriate for the person's fat mass. In Farooqi's 2007 selected cohort, receptor variants impaired signaling without requiring disproportionately high circulating leptin. Neither a high result nor a value appropriate for adiposity excludes a receptor defect. Adding leptin cannot restore a receptor that lacks signaling function. [9]
Common obesity usually has abundant hormone with reduced effectiveness. This pattern differs from rare absent-ligand disease. Transport and signaling mechanisms may contribute, but common obesity is heterogeneous. The shorthand “leptin resistance” does not establish a specific molecular lesion, exclude other contributors to appetite, or imply that every leptin action has stopped. [1][18]
Generalized lipodystrophy has too little adipose tissue despite severe metabolic disease. Loss of normal fat storage capacity promotes ectopic lipid deposition, severe insulin resistance and hypertriglyceridemia. Low leptin reflects the small adipose source. A muscular appearance or low subcutaneous fat does not guarantee metabolic health. Diagnose the distribution of fat loss and its metabolic consequences, rather than using diabetes as a synonym for excess body fat. [14]
Worked example. Two adolescents have diabetes. One has abundant subcutaneous fat and plentiful leptin. The other has had near-total subcutaneous fat absence since infancy, very low leptin and severe hypertriglyceridemia. The second pattern suggests generalized lipodystrophy. Similar glucose problems can arise from very different adipose biology.
Predict whether normal leptin for fat mass excludes a genetic appetite disorder
No. A functioning hormone assay does not test receptor signaling. The history of extreme early hyperphagia can still justify genetic evaluation.
Understand conservation without making it destiny
After weight loss, lower leptin can contribute to greater hunger and lower energy expenditure. Some expenditure reduction simply reflects a smaller body; adaptive thermogenesis is the additional reduction beyond that expected from altered body composition. These responses can make maintenance harder. They do not demonstrate poor effort, guarantee regain, or prove permanent damage to the hypothalamus. Treatment and support can be adjusted over time. [10]
Rosenbaum's 2005 experiment studied ten inpatients at usual weight and after a maintained 10% weight reduction. Restoring leptin toward each person's prior level reversed selected changes in expenditure, muscle efficiency, autonomic activity and thyroid hormones. This is mechanistic evidence from a small controlled setting. It does not establish a durable maintenance treatment for the general population or support prescribing metreleptin for common obesity. [10][15]
Low energy availability can also reduce hypothalamic reproductive drive. In an adult with amenorrhea, low estradiol accompanied by low or inappropriately normal LH and FSH suggests central suppression. Primary ovarian failure usually gives low estradiol with increased FSH because negative feedback is lost. Exclude pregnancy and evaluate alternative causes before diagnosing functional hypothalamic amenorrhea. Leptin is a permissive energy signal, not a solitary puberty trigger or a direct instruction to ovulate. [13]
Chan's 2003 short-term fasting experiment in healthy lean men showed that leptin replacement prevented selected gonadal and TSH-secretion changes. It did not normalize all starvation responses, including the T3 and reverse-T3 changes. Energy deficit also affects growth-related, immune and bone physiology through multiple pathways. Congenital deficiency studies found immune and age-dependent endocrine abnormalities, but normal prepubertal gonadotropins cannot establish hypogonadotropic hypogonadism in every young child. [2][8][13]
Worked example. A runner develops amenorrhea after sustained under-fueling. Pregnancy testing is negative; estradiol is low and FSH is not increased. Reduced central drive fits better than primary ovarian failure. Restoring energy availability addresses the initiating problem while other causes are assessed.
Predict how markedly increased FSH would change that localization
Increased FSH despite low estradiol indicates loss of ovarian negative feedback. That pattern redirects evaluation toward primary ovarian dysfunction rather than explaining everything through low leptin.
Ask a question the assay can answer
A serum leptin result measures immunoreactive hormone, not satiety, receptor competence or a resistance score. There is no accepted routine diagnostic cutoff for leptin resistance. A laboratory reference interval is not a threshold for diagnosing that mechanism. Common obesity does not require leptin measurement to establish its diagnosis or select ordinary treatment. [1][19]
Interpret a targeted measurement alongside body composition, sex, hormonal context, recent intake and sampling time. Laboratory reference information can depend on sex and BMI. Renal uptake contributes to clearance, and inflammatory signaling can alter circulating levels. These factors make a single universal number misleading. They do not provide a formula for correcting every result. [19][20][21][22]
Extreme obesity beginning before age five with extreme hyperphagia, associated syndromic findings or a relevant family history supports consideration of genetic evaluation under Endocrine Society guidance. Very low leptin despite marked adiposity can help focus that assessment on LEP. However, Wabitsch's 2015 report described a secreted variant detectable by immunoassay that failed to activate the receptor. Detectable hormone therefore does not exclude every form of functional ligand deficiency. Specialist molecular and functional interpretation matters. [12][11]
Worked example. A child has extreme hyperphagia from infancy and abundant measured leptin. In a research assay, the child's purified leptin fails on a normal receptor, while reference leptin works. The experiment localizes the defect to the ligand's biological activity. The assay result alone could have missed it. In suspected lipodystrophy, likewise, no single leptin level establishes or excludes the clinical diagnosis. [11][14]
Predict which conclusion survives an unexpectedly normal leptin result in extreme early hyperphagia
The phenotype still warrants investigation. Normal immunoreactivity does not exclude an inactive LEP variant or a signaling defect in LEPR.
Match evidence and indication to the actual phenotype
In congenital LEP deficiency, replacement can supply a missing functional signal. Farooqi's 1999 single-child report and 2002 three-child follow-up documented important appetite and fat-mass responses, with endocrine and immune findings in the latter. These rare-disease reports support specialist care. They are distinct from the current US approved indication and cannot be generalized to receptor failure or common obesity. [7][8]
The US MYALEPT label linked by the manufacturer, revised March 2024 and checked September 23, 2026, indicates metreleptin as an adjunct to diet for complications of leptin deficiency in congenital or acquired generalized lipodystrophy. It is contraindicated in general obesity not associated with congenital leptin deficiency. The congenital-deficiency exception in that contraindication is not a separate FDA-approved indication. Safety and effectiveness for partial lipodystrophy and liver disease, including NASH, are not established. It is not indicated for HIV-related lipodystrophy or metabolic disease without generalized lipodystrophy. [15]
Metreleptin requires the MYALEPT REMS because of neutralizing-antibody and lymphoma risks. Antibodies can impair endogenous leptin or treatment activity. Lymphoma has occurred in acquired generalized lipodystrophy with and without treatment; do not claim that every event was caused by the drug. Glucose must be monitored when insulin or insulin secretagogues are used because hypoglycemia may require substantial medication adjustment. [15]
Heymsfield's 1999 randomized dose-escalation study did find dose-related weight loss in participants without congenital deficiency. Responses varied, and baseline leptin did not predict the weight response. Saying leptin never affects common obesity would overstate the evidence. That historical experiment still does not establish routine effectiveness, long-term benefit or an approved obesity indication. No leptin diet or supplement follows from these findings. [16][15]
Worked example. A patient with generalized lipodystrophy and diabetes begins specialist metreleptin therapy while using insulin. Improving metabolic control can make the prior insulin dose excessive. Monitor glucose and reassess the glucose-lowering regimen. A similar liver-fat finding in ordinary obesity does not establish metreleptin eligibility.
Predict whether fatty liver alone supplies the missing treatment indication
No. Liver disease is not an established indication. The approved phenotype is complications of leptin deficiency with congenital or acquired generalized lipodystrophy.
Use the whole pattern
Locate the problem before choosing an intervention. Compare adipose stores with current energy availability, separate measurable hormone from biological activity, then test whether the receptor and downstream pathway can respond. Match the clinical phenotype to the actual treatment evidence.
Worked example. Severe infant-onset hyperphagia plus very low leptin despite abundant fat supports investigating ligand deficiency. Change the experiment so reference leptin also fails on the patient's receptor, and the localization shifts toward receptor signaling. The same hunger symptom does not make the two interventions interchangeable.
Predict what a high leptin result leaves unanswered
It leaves receptor function and downstream responsiveness unanswered. The clinical history and any targeted functional evidence determine the next inference.
Case 1
Show answer and explanations for case 1
A. Failure of LEPR signaling; supplying ligand should restore receptor function (Why this does not fit)
LEPR dysfunction can coexist with leptin appropriate for a large fat mass. Supplying leptin does not restore absent receptor signaling.
B. Deficient LEP production or secretion; supplying ligand may restore signaling (Best answer)
Abundant adipose tissue without recent energy restriction should not produce an absent energy-store signal. A defect in LEP production or secretion can leave the ligand absent while the receptor remains responsive. Functional leptin can then supply the missing input, supporting specialist evaluation for congenital deficiency.
C. Loss of adipose tissue; supplying ligand should correct the low adipose source (Why this does not fit)
Generalized adipose loss can explain very low leptin in lipodystrophy. This child has abundant subcutaneous fat, so loss of the hormone-producing tissue does not explain the mismatch.
D. Recent energy deficit; supplying ligand should replace an acquired low signal (Why this does not fit)
Recent energy deficit can suppress leptin secretion before substantial fat loss. Persistent hyperphagia from infancy and the absence of caloric restriction favor a congenital ligand problem over an acquired fasting response.
Takeaway: Compare leptin with adipose stores and recent intake before inferring what replacement could restore.
A. Use the leptin value to choose a replacement dose sufficient to suppress hunger (Why this does not fit)
The measured leptin is abundant and compatible with the patient's fat mass. No validated leptin-resistance cutoff or routine replacement target follows from this result.
B. Prioritize LEP sequencing because persistent hunger outweighs the adult time course (Why this does not fit)
Extreme hyperphagia with obesity beginning in early childhood would make genetic evaluation more compelling. Gradual adult-onset obesity with abundant leptin does not specifically prioritize congenital LEP deficiency.
C. Treat the high leptin as evidence that central appetite signaling is fully effective (Why this does not fit)
It measures circulating immunoreactive leptin rather than neural responsiveness. A high concentration can coexist with reduced biological effectiveness, so it cannot establish intact appetite regulation.
D. Base treatment on the clinical obesity assessment because the value does not grade resistance or justify replacement (Best answer)
Adipocytes are supplying leptin rather than demonstrating a classic absent-ligand state. They do not define a quantitative resistance grade or identify an individual signaling lesion. MYALEPT is contraindicated in general obesity not associated with congenital leptin deficiency.
Takeaway: High leptin does not supply a validated resistance score or an indication for leptin replacement.
A. STAT3 activation remains absent; MC4R activation increases (Best answer)
Increasing leptin cannot restore STAT3 activation through a receptor stipulated to lack signaling function. A direct agonist can activate the separately intact MC4R pathway without requiring LEPR.
B. STAT3 activation increases; MC4R activation increases (Why this does not fit)
MC4R activation can increase because that downstream receptor is explicitly intact. More leptin still encounters the same nonfunctional LEPR, so ligand abundance does not restore the missing response.
C. STAT3 activation remains absent; MC4R activation remains absent (Why this does not fit)
The demonstrated defect is in LEPR-dependent STAT3 activation. An intact MC4R can respond to a direct agonist even when the upstream leptin receptor fails.
D. STAT3 activation increases; MC4R activation remains absent (Why this does not fit)
The child's LEPR lacks signaling function despite exposure to reference leptin. The downstream MC4R is intact, so the predicted responses are the reverse of this option.
Takeaway: Localize the failed receptor before predicting whether an upstream or downstream stimulus can work.
A. Large hidden adipose stores produce excessive leptin that directly causes the diabetes (Why this does not fit)
Diabetes and hypertriglyceridemia can occur when normal adipose storage capacity is deficient. Generalized subcutaneous fat absence and very low leptin contradict excess adipose-derived leptin as the supplied explanation.
B. Restricted caloric intake lowers leptin and is the main cause of the lifelong fat distribution (Why this does not fit)
Energy restriction can lower leptin without an inherited signaling defect. Near-total subcutaneous fat absence documented since infancy, together with severe insulin resistance, favors generalized lipodystrophy.
C. Deficient adipose storage promotes ectopic lipid, while the small adipose source produces little leptin (Best answer)
Limited adipose storage can redirect lipid toward ectopic sites such as the liver. A small adipose source also produces little leptin, so severe metabolic disease can coexist with low leptin.
D. An isolated LEPR defect prevents leptin action and accounts for the absent subcutaneous fat (Why this does not fit)
Severe LEPR deficiency usually produces hyperphagic obesity with substantial fat mass. The supplied phenotype is generalized fat absence rather than increased adiposity.
Takeaway: Low adipose mass can produce profound metabolic disease through impaired storage and loss of endocrine signaling.
A. The smaller body explains all of the expenditure change, making the leptin decline physiologically irrelevant (Why this does not fit)
A smaller body ordinarily requires less energy. The measured reduction beyond that predicted by body composition indicates an adaptive component that the smaller-body explanation alone omits.
B. A relative leptin decline contributes to conservation responses in addition to the effect of a smaller body (Best answer)
Expenditure below the body-composition prediction is consistent with adaptive thermogenesis. A decline from the prior leptin signal can contribute to hunger and conservation without absolute hormone absence. These responses can increase the effort required for maintenance without making regain inevitable.
C. Continuing negative energy balance explains the findings without any adaptation during weight maintenance (Why this does not fit)
The patient has maintained the reduced weight for several weeks. Conservation responses can persist at a stable reduced weight rather than requiring continuing weight loss.
D. Less time spent physically active explains the extra expenditure reduction without a physiological adaptation (Why this does not fit)
Recorded physical activity duration is unchanged. The expenditure reduction beyond the body-composition prediction cannot be assigned solely to less time spent active.
Takeaway: Separate the energy cost of a smaller body from additional adaptation, and avoid treating that adaptation as destiny.
A. Proportional loss of hormone-producing adipose tissue is sufficient to explain the leptin decline (Why this does not fit)
Measured fat mass remains at 98% of the participant's fed baseline. The disproportionate hormone decline requires considering regulation beyond the small change in fat mass.
B. The serum decline quantifies a newly acquired defect in central receptor responsiveness (Why this does not fit)
It measures circulating immunoreactive hormone rather than receptor responsiveness. A large decline during documented caloric restriction supports acute signal regulation without measuring an acquired receptor defect.
C. The serum decline establishes bioinactive hormone despite preserved adipocyte secretion (Why this does not fit)
No functional ligand-receptor assay was performed. It shows an acute hormone decline disproportionate to fat loss, not proof of a newly bioinactive ligand.
D. Acute nutritional regulation contributes to the leptin decline beyond the small change in fat mass (Best answer)
A large hormone decline with little fat loss indicates an acute nutritional component. Changes in secretion can precede substantial fat gain when energy availability improves.
Takeaway: Leptin can report a change in energy availability before body composition changes substantially.
A. The receptor cannot use an associated cytoplasmic kinase to initiate signaling (Best answer)
Leptin can reach and bind the receptor in this cell system. LEPRb uses an associated kinase rather than its own intrinsic tyrosine-kinase domain to initiate the STAT response.
B. The receptor's intrinsic tyrosine-kinase catalytic domain has lost activity (Why this does not fit)
The relevant kinase is the associated JAK2 protein. The experiment disrupts kinase association, not an intrinsic catalytic domain within LEPR.
C. Reduced passage of leptin into the brain prevents hormone arrival at the receptor (Why this does not fit)
Direct application of leptin to cultured cells bypasses delivery into the brain. Normal receptor binding confirms hormone arrival despite the subsequent signaling failure.
D. Defective adipocyte secretion prevents enough leptin from reaching the culture (Why this does not fit)
The researchers apply leptin directly to the culture. Receptor binding occurs normally, localizing the interruption after ligand binding rather than at secretion.
E. STAT3 cannot bind nuclear DNA despite normal receptor-associated kinase activation (Why this does not fit)
The receptor's intracellular change prevents JAK2 association. That explanation assumes intact receptor-associated kinase activation despite the demonstrated interruption before STAT3 activation.
Takeaway: Normal ligand binding does not establish successful intracellular signaling.
A. Increase POMC expression in the donor culture while leaving AgRP unchanged (Why this does not fit)
It could change the supply of the alpha-MSH agonist. Changing agonist supply would not isolate AgRP's contribution as directly as reducing AgRP with alpha-MSH held constant.
B. Block NPY receptors while keeping AgRP and alpha-MSH constant (Why this does not fit)
NPY promotes feeding through its own receptors, whereas AgRP opposes melanocortin signaling at MC4R. Keeping AgRP unchanged leaves the suspected MC4R antagonism in place.
C. Reduce AgRP in the mixture while keeping alpha-MSH constant (Best answer)
The reporter's MC4R can respond when tested without the inhibitory mixture. That comparison isolates the proposed antagonist's contribution to the reduced MC4R output. Recovery of MC4R output would support AgRP-mediated opposition to the same alpha-MSH input.
D. Increase MC4R abundance in the reporters while leaving the peptide mixture unchanged (Why this does not fit)
The existing receptors can respond normally to purified alpha-MSH. Changing receptor abundance would not specifically isolate the contribution of AgRP in the mixture.
Takeaway: To test an antagonist's contribution, change the antagonist while holding the agonist input constant.
A. Increase leptin while relying on the same impaired POMC processing (Why this does not fit)
Leptin already activates STAT3 and increases POMC expression in the model. Impaired conversion to alpha-MSH still limits the signal delivered to MC4R.
B. Supply alpha-MSH directly to the responsive downstream cells (Best answer)
The interruption occurs between POMC expression and availability of its alpha-MSH product. Downstream cells respond to direct alpha-MSH, so supplying that agonist bypasses the processing defect.
C. Increase CART delivery to the responsive downstream cells (Why this does not fit)
The missing effective product is alpha-MSH derived from POMC. CART coexpression does not make it the alpha-MSH ligand whose direct addition restores the tested MC4R response.
D. Reduce AgRP in the existing mixture without supplying additional alpha-MSH (Why this does not fit)
Less AgRP can reduce opposition to MC4R activation. The demonstrated interruption is poor alpha-MSH production, and the supplied successful challenge directly replaces that missing agonist.
Takeaway: A successful downstream challenge can identify where an upstream signal fails.
A. Primary ovarian follicular dysfunction with loss of ovarian negative feedback (Why this does not fit)
Primary ovarian dysfunction generally increases FSH when estradiol falls. Non-elevated FSH despite low estradiol favors reduced central reproductive drive.
B. Prolactin-mediated inhibition of hypothalamic reproductive signaling (Why this does not fit)
Hyperprolactinemia can inhibit the reproductive axis. Prolactin is normal, while the history instead documents sustained low energy availability.
C. Primary thyroid dysfunction with secondary reproductive-axis suppression (Why this does not fit)
A primary thyroid disorder would require supporting thyroid-function abnormalities. Thyroid studies are normal, whereas low estradiol with non-elevated gonadotropins follows sustained under-fueling.
D. Energy-deficit-associated reduction of hypothalamic reproductive drive (Best answer)
The gonadotropin response is inadequate for the low estradiol, favoring central suppression. Sustained under-fueling with increased training can lower permissive energy signals, including leptin. Functional hypothalamic amenorrhea remains a diagnosis of exclusion rather than a diagnosis made by leptin alone.
Takeaway: Use gonadotropins to localize low sex steroids, then assess energy availability and competing causes.
A. Functional hypothalamic suppression, with lower leptin explaining the entire endocrine pattern (Why this does not fit)
Functional hypothalamic suppression usually produces low or inappropriately normal gonadotropins. Lower leptin does not explain repeatedly high FSH in the presence of low estradiol.
B. Hyperprolactinemic central suppression causing the low ovarian hormone output (Why this does not fit)
Prolactin is within the normal range. Repeatedly high FSH with low estradiol supports reduced ovarian negative feedback.
C. Primary ovarian dysfunction, which can coexist with an acquired nutritional leptin decline (Best answer)
The pituitary is responding to reduced ovarian negative feedback. Energy restriction can lower leptin without being the explanation for the ovarian feedback pattern.
D. Pituitary gonadotroph failure, with lower leptin supporting the central localization (Why this does not fit)
FSH secretion is increased rather than deficient. Leptin alone cannot override the gonadotropin pattern or establish pituitary failure.
Takeaway: A nutritional explanation must still fit the direction of endocrine feedback.
A. The appetite response can coexist with age-appropriate prepubertal gonadotropins (Best answer)
The supplied clinical response supports an effect of replacement on appetite regulation. Leptin is permissive for reproductive maturation, so effective replacement does not require precocious activation of the gonadal axis.
B. The unchanged gonadotropins establish LEPR failure despite the appetite response (Why this does not fit)
Prepubertal gonadotropins can be appropriate in a 7-year-old. That pattern does not establish receptor failure, especially when appetite has responded to replacement.
C. The dose should be increased until gonadotropins enter a pubertal range (Why this does not fit)
Treatment supplies a deficient energy-sufficiency signal. The evidence supports age-dependent reproductive effects rather than using premature puberty as a dose target.
D. The prepubertal results confirm persistent hypogonadotropic hypogonadism (Why this does not fit)
Reproductive hormone concentrations must be interpreted against developmental stage. Values within the prepubertal range do not establish pathological hypogonadism in this child.
Takeaway: Age-appropriate prepubertal findings must not be relabeled as endocrine failure.
A. LEPR failure; additional functional leptin should be ineffective (Why this does not fit)
It responded normally to the reference ligand. The child's purified leptin failed on a normal receptor, locating the demonstrated defect in the ligand.
B. Poor entry of leptin into the brain; increasing transport should correct the assay (Why this does not fit)
Purified ligand is applied directly to receptor-bearing cells. The failed response occurs despite direct access, so impaired brain entry does not explain the assay result.
C. A downstream MC4R defect; supplying alpha-MSH should restore the measured LEPR response (Why this does not fit)
The comparison measures activation through LEPR, not downstream MC4R function. The receptor system can signal when it receives functional leptin, pointing to the patient's ligand rather than MC4R.
D. Bioinactive LEP product; functional replacement may restore signaling through the intact receptor (Best answer)
The protein is recognized by the immunoassay, which does not establish biological activity. The child's ligand fails while the child's receptor responds to reference ligand. Functional leptin replacement may restore the missing signal under specialist care.
Takeaway: Immunoreactivity and biological activity are different measurements.
A. Repeat leptin measurements until a result falls below the reference interval before considering genetics (Why this does not fit)
LEPR dysfunction can occur with leptin appropriate for fat mass. It could delay evaluation of an extreme early hyperphagic phenotype that already supports genetic assessment.
B. Specialist genetic evaluation of early-onset obesity pathways, including ligand and receptor defects (Best answer)
Extreme hyperphagia and severe obesity beginning before age five support considering a genetic appetite disorder. Monogenic appetite disorders can occur without dysmorphism and without absent circulating leptin.
C. Broad pituitary and adrenal hormone screening as the initial explanation for the obesity (Why this does not fit)
Attenuated stature or height velocity would make routine endocrine investigation more relevant. Preserved growth with extreme early hyperphagia more specifically supports genetic appetite-pathway assessment.
D. Observation through puberty because a genetic appetite disorder should also delay development (Why this does not fit)
LEPR and other appetite-pathway disorders may present with otherwise age-appropriate development. The severe early onset and extreme hyperphagia already meet features that warrant considering genetic testing.
Takeaway: Use early onset and extreme hyperphagia to guide genetic assessment; a leptin result alone does not close it.
A. Reduced clearance could contribute; the direction of central responsiveness remains undetermined (Best answer)
The concentration also depends on clearance, including renal uptake and degradation. Altered clearance could contribute to the rise, so the result does not independently quantify a change in hypothalamic responsiveness.
B. Increased adipose secretion is established; the direction of central responsiveness remains undetermined (Why this does not fit)
Both hormone production and clearance contribute to the concentration. It does not, and changed kidney function provides an additional clearance explanation.
C. Reduced clearance could contribute; stronger central satiety signaling is thereby established (Why this does not fit)
Reduced clearance can increase circulating leptin independently of a larger adipose source. The neural response is unmeasured, so greater circulating abundance does not establish greater satiety signaling.
D. Reduced clearance could contribute; worsening central receptor resistance is thereby established (Why this does not fit)
It can contribute to a higher leptin concentration through altered clearance. It does not measure receptor function or prove worsening central resistance.
Takeaway: Account for hormone clearance before using a concentration change to infer altered biological responsiveness.
A. A sustained rise in total expenditure was the principal demonstrated cause of fat loss (Why this does not fit)
Total expenditure would need to be higher at follow-up. Total expenditure was similar, while food intake decreased.
B. A direct adipocyte-destruction effect was established because fat mass declined (Why this does not fit)
Fat-mass decline identifies a lost energy store, not the mechanism producing the energy deficit. Reduced intake with similar total expenditure supports an intake-mediated deficit without establishing adipocyte destruction.
C. Reduced energy intake was the main demonstrated contributor, without proving identical responses in common obesity (Best answer)
Reduced energy intake can make intake fall below expenditure. The report involved a child with a missing leptin signal, not a population with common hyperleptinemic obesity.
D. Leptin had no appetite effect because total energy expenditure did not increase (Why this does not fit)
Food intake decreased during replacement. Stable expenditure does not negate an intake-mediated contribution to fat loss.
Takeaway: Energy balance can improve through lower intake without a demonstrated rise in total expenditure.
A. An adult with common obesity, high leptin and diabetes despite standard therapy (Why this does not fit)
The described patient has common obesity rather than generalized loss of adipose tissue. General obesity not associated with congenital leptin deficiency is a contraindication.
B. An adolescent with partial limb fat loss, retained truncal fat and severe hypertriglyceridemia (Why this does not fit)
Regional fat loss with retained truncal stores describes a partial rather than generalized pattern. The US label does not establish safety and effectiveness for partial lipodystrophy.
C. A child with congenital LEP deficiency and abundant adipose tissue, without lipodystrophy (Why this does not fit)
Rare-disease reports document benefit from replacing a missing functional ligand. Congenital LEP deficiency without generalized lipodystrophy is not the separate approved indication in the current US label.
D. An adolescent with congenital generalized lipodystrophy, low leptin and severe metabolic complications (Best answer)
Congenital generalized lipodystrophy supplies the generalized adipose-loss phenotype. Adjunctive replacement for complications of leptin deficiency in that phenotype matches the approved indication.
E. An adult with HIV-related lipodystrophy, diabetes and severe hypertriglyceridemia (Why this does not fit)
Diabetes and hypertriglyceridemia do not determine the cause or distribution of lipodystrophy. MYALEPT is not indicated for HIV-related lipodystrophy.
Takeaway: Clinical plausibility, published benefit and an FDA-approved indication are distinct judgments.
A. Improved metabolic control may make the previous insulin exposure excessive, requiring monitored adjustment (Best answer)
The documented glucose of 48 mg/dL establishes hypoglycemia. Improved metabolic control can reduce glucose-lowering requirements even when meals and insulin administration are unchanged. The insulin regimen needs prompt reassessment with glucose monitoring rather than automatic continuation at the prior exposure.
B. Neutralization of both endogenous and administered leptin is the most likely explanation for the glucose improvement (Why this does not fit)
Loss of treatment efficacy with worsening metabolic control or severe infection raises that concern. Glucose control improved and then became excessive on unchanged insulin, fitting hypoglycemia from the combined regimen more directly.
C. Progressive insulin resistance requires an increase in the existing insulin regimen (Why this does not fit)
The patient has symptomatic low glucose rather than worsening hyperglycemia. Increasing insulin would intensify the glucose-lowering exposure that now requires reassessment.
D. Reduced food intake is the established cause, so insulin needs no review (Why this does not fit)
Meals are explicitly unchanged. Metreleptin with insulin can cause hypoglycemia, making review of insulin requirements necessary.
Takeaway: A prior glucose-lowering dose may become excessive after the metabolic response changes.
A. Measure total circulating leptin concentration without a functional antibody assessment (Why this does not fit)
An immunoreactive hormone concentration does not establish functional neutralization. The concern is whether anti-drug antibodies impair biological activity, not simply how much leptin the assay detects.
B. Test for anti-metreleptin antibodies with neutralizing activity (Best answer)
Severe infection and possible loss of efficacy are reasons to evaluate neutralizing anti-metreleptin antibodies. They can interfere with administered metreleptin or endogenous leptin activity, rather than merely registering as a harmless assay finding.
C. Measure anti-metreleptin binding antibodies without determining neutralizing activity (Why this does not fit)
Antibody binding and neutralizing activity are different properties. The specific concern is neutralizing activity that can interfere with leptin action.
D. Characterize circulating lymphocytes without assessing drug-neutralizing activity (Why this does not fit)
Acquired generalized lipodystrophy carries lymphoma concerns that may warrant appropriate hematologic assessment. Lymphocyte characterization does not test whether antibodies neutralize metreleptin or endogenous leptin.
Takeaway: Severe infection or loss of metreleptin efficacy should prompt evaluation of neutralizing antibodies, alongside other causes.
A. The absence of a baseline-leptin association shows that none of the participants responded to administered leptin (Why this does not fit)
The study reported increasing weight loss with increasing leptin dose. Baseline leptin did not identify who would lose weight, which is different from proving no treatment response.
B. The largest dose group's average response establishes a predictable benefit for this individual (Why this does not fit)
Substantial within-group variation means the average does not describe every participant's response. The trial did not find baseline leptin predictive of weight loss.
C. Some biological response is supported, but neither a selection threshold nor routine current use follows (Best answer)
The randomized trial reported dose-related weight loss despite variable individual outcomes. It did not establish baseline leptin as a predictor of the weight response. The current label contraindicates general obesity not associated with congenital leptin deficiency.
D. The shared diet intervention means the reported randomized dose-response comparison contains no information about leptin (Why this does not fit)
A common dietary intervention does not by itself erase information from a randomized dose comparison. The trial's design, variable responses and studied setting limit extrapolation without requiring dismissal of its reported dose-related finding.
Takeaway: Do not confuse a historical biological response with a validated selection test or current treatment indication.
A. Leptin contributes to selected endocrine responses; persistent changes imply additional fasting mechanisms (Best answer)
It supports a causal contribution of falling leptin to those measured neuroendocrine responses. They prevent attributing every fasting response solely to leptin loss. A small short-term study in healthy men does not establish a general treatment for prolonged undernutrition or amenorrhea.
B. Leptin replacement completely restored thyroid physiology because TSH secretion responded (Why this does not fit)
T3 and reverse T3 remained affected by fasting despite the TSH-secretion response. An upstream secretory response does not establish normalization of every downstream hormone measure.
C. Leptin had no role in fasting adaptation because T3 did not normalize (Why this does not fit)
Selected gonadal-axis and TSH-secretion changes were prevented during replacement. An uncorrected endpoint limits the scope of the effect without negating the endpoints that responded.
D. Persistent T3 and reverse-T3 changes establish primary thyroid-gland failure induced by the study (Why this does not fit)
The changes occurred during a controlled short-term fasting experiment. It shows incomplete reversal by leptin, not proof of newly induced primary thyroid-gland failure.
Takeaway: Separate the endpoints that respond to a perturbation from those that do not.
A. Everyone who loses 10% of body weight will regain it unless leptin is replaced (Why this does not fit)
It measured selected physiological adaptations under controlled inpatient conditions. It did not establish that every patient will regain weight without replacement.
B. The reversal proves that the original obesity was caused by congenital LEP deficiency (Why this does not fit)
The investigators restored concentrations toward each participant's own pre-loss level. A relative fall after weight reduction does not establish an inherited inability to produce functional leptin.
C. The experiment establishes a long-term outpatient metreleptin maintenance regimen (Why this does not fit)
Selected adaptations reversed during the controlled experimental intervention. A durable outpatient regimen would require evidence on longer-term benefits and harms in that setting.
D. A relative leptin decline can contribute to weight-reduction adaptations, without establishing long-term replacement benefit (Best answer)
It supports a contribution of relative leptin insufficiency to selected adaptations after weight reduction. The small inpatient experiment did not establish durable prevention of outpatient weight regain.
Takeaway: Mechanistic reversal supports a physiological role without establishing a long-term treatment program.
A. The exception means FDA approval specifically includes all congenital LEP deficiency (Why this does not fit)
It limits the wording of the general-obesity contraindication. An exception to a contraindication does not add an indication absent from the indications section.
B. Published replacement responses support specialist consideration, but the current approved indication remains generalized lipodystrophy (Best answer)
They support clinical benefit from supplying a missing functional ligand in selected patients. Its approved indication specifies complications of leptin deficiency with congenital or acquired generalized lipodystrophy.
C. No clinical evidence supports replacement because the child lacks generalized lipodystrophy (Why this does not fit)
Farooqi and colleagues reported responses in congenital LEP deficiency. Published benefit and an approved indication are separate evidence and regulatory categories.
D. The general-obesity contraindication applies equally because the child has abundant adipose tissue (Why this does not fit)
The child has confirmed congenital LEP deficiency. The wording excludes obesity associated with congenital leptin deficiency from the stated general-obesity contraindication.
Takeaway: Read the indication and contraindication separately; neither replaces appraisal of the clinical evidence.
A. The concentration difference identifies a pathogenic LEPR variant in each participant with obesity (Why this does not fit)
The comparison did not include genetic testing. They cannot identify a pathogenic LEPR variant in an individual participant.
B. The lower proportional CSF rise means adipocytes failed to secrete leptin (Why this does not fit)
Serum leptin is much higher in the participants with obesity. The smaller proportional rise is in the CSF compartment, not evidence that adipocyte secretion is absent.
C. Limited central delivery is plausible; the full cause of reduced responsiveness remains unresolved (Best answer)
Central leptin availability may not rise in direct proportion to serum abundance. Concentration measurements do not directly test receptor function or establish all contributors to reduced responsiveness.
D. The serum increase proves that hypothalamic target cells receive a proportionately stronger effective signal (Why this does not fit)
The CSF concentration increases much less proportionally than the serum concentration. Target-cell responsiveness was not measured, so effective signaling cannot be inferred from serum abundance alone.
Takeaway: Separate circulating supply, central delivery and target response when interpreting a hormone gradient.
A. Neither low leptin nor liver disease makes partial lipodystrophy an established US indication (Best answer)
The confirmed fat-loss distribution is partial, with retained truncal adipose tissue. The label does not establish safety and effectiveness for partial lipodystrophy or liver disease, so those findings do not broaden the approved indication.
B. The low leptin value makes any lipodystrophy subtype an approved indication (Why this does not fit)
The approved category is congenital or acquired generalized lipodystrophy. Low leptin does not convert partial lipodystrophy into generalized lipodystrophy.
C. Steatotic liver disease supplies an independent approved indication regardless of fat distribution (Why this does not fit)
The current label does not establish safety and effectiveness for treating liver disease, including NASH. Steatosis does not create a separate labeled indication for this patient.
D. All partial lipodystrophy is explicitly contraindicated under the same provision as common obesity (Why this does not fit)
It states that safety and effectiveness have not been established. That limitation should not be rewritten as the separate contraindication for general obesity not associated with congenital leptin deficiency.
Takeaway: A low laboratory value or liver manifestation does not erase the label's phenotype-specific limits.
